Genomic Vision: convening of a new Combined Shareholders’ Meeting on August 10, 2020

Bagneux (France) - Genomic Vision (FR0011799907 – GV), a company specialized in in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases, and in the development of applications for life sciences research (LSR), informs its shareholders that Combined Shareholders’ Meeting of July 24, 2020, held in camera, was unable to deliberate as the required quorum was not reached.

Genomic Vision would like to thank the shareholders who expressed their vote by mail and counts on the mobilization of all its shareholders, both individuals and institutions, to meet the quorum and majority conditions required by law on second convocation (no quorum required for decisions falling within the scope of the Ordinary General Meeting and a quorum of one fifth of the shares with voting rights for decisions falling within the scope of the Extraordinary General Meeting).

Genomic Vision’s combined general meeting on second notice will be held on Monday, August 10, 2020 at 10:00 a.m. at the company’s registered office, 80-84 rue des Meuniers, Building E, 92220 Bagneux, also in camera, to deliberate on the same agenda.

In accordance with current regulations and AMF recommendations, Genomic Vision shareholders are requested to cast their votes exclusively by mail, prior to the General Meeting, by voting by post or by giving a proxy to the Chairman of the Meeting, in accordance with the procedures detailed in the company’s notice of meeting published in the BALO of 19 June 2020.

The votes of shareholders who voted by post at the first meeting remain valid and will be counted for the meeting on second call.

All preparatory documents remain available on request from the company, or can be consulted on the company’s website, under the heading Investors/General Meetings.

***
ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

***

CONTACTS

Genomic Vision
Dominique Rémy-Renou
CEO
Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com

Ulysse Communication
Press Relations
Bruno Arabian
Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com

NewCap
Investor Relations & Strategic Communications
Tel.: +33 1 44 71 94 94
gv@newcap.eu

Member of the CAC® Mid & Small and CAC® All-Tradable indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document dated March 29, 2019 filed with the AMF under reference number R19-004, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.